| Literature DB >> 30775593 |
Abstract
INTRODUCTION: Despite the development of non-invasive tools of investigations for congenital heart diseases (CHDs), still the role of diagnostic cardiac catheterization (DCC) cannot be undermined. The study aimed to analyze the clinical profile of indicated CHDs cases at our center for DCC to evaluate the contribution of DCC in patients' management plans.Entities:
Keywords: cardiac angiography; congenital heart diseases; hemodynamic data; pulmonary vascular resistance index
Year: 2018 PMID: 30775593 PMCID: PMC6374569 DOI: 10.5114/amsad.2018.76824
Source DB: PubMed Journal: Arch Med Sci Atheroscler Dis ISSN: 2451-0629
Clinical profile of CHDs of the studied groups
| Parameter | Number | % in same group | % in total group ( |
|---|---|---|---|
| Group I ( | |||
| VSD | 15 | 60 | 24.5 |
| CAVCDs | 5 | 20 | 8.1 |
| DORV | 3 | 12 | 4.9 |
| TGA/ASD/VSD | 2 | 8 | 3.2 |
| Group II ( | |||
| TOF | 17 | 47.2 | 27.2 |
| TOF/PA | 3 | 8.3 | 4.9 |
| VSD/PS | 9 | 25 | 14.7 |
| PS/LPA | 5 | 13.9 | 8.1 |
| TGA/PS | 1 | 2.8 | 1.6 |
| DCRV | 1 | 2.8 | 1.6 |
VSD – ventricular septal defect, CAVCDs – complete atrioventricular septal defects, TOF – tetralogy of Fallot, PA – pulmonary atresia, ASD – atrial septal defect, PS – pulmonary stenosis, TGA – transposition of great arteries, DORV – double outlet right ventricle, DCRV – double chamber right ventricle.
Distribution of the studied cases according to demographic data
| Data | Group I ( | Group I ( | Total number ( |
|---|---|---|---|
| Age, median (range) [months]: | 24 (4–120) | 30 (6–144) | 26 (4–144) |
| No. of cases ≤ 12 m | 6 (24%) | 7 (19.4%) | 13 (21.3%) |
| No. of cases > 12–24 | 9 (36%) | 7 (19.4%) | 16 (26.2%) |
| No. of cases > 24–36 | 5 (20%) | 6 (16.7%) | 11 (18%) |
| No. of cases > 36–48 | 2 (8%) | 4 (11.1%) | 6 (9.8%) |
| No. of cases > 48 | 3 (12%) | 12 (33.3%) | 15 (24.6%) |
| Weight, median (range) [kg] | 12 (4–30) | 11 (6–36) | 11 (4–36) |
| Height, mean (range) [cm] | 80.8 ±15.2 | 89.4 ±22.9 | 85.9 ±20.4 |
| BMI, median (range) [kg/m2] | 17.4 (10.4–35.8) | 15.9 (12.8–32) | 16.1 (10.4–35.3) |
| Median SAO2 % (room air) | 94 (78–98) | 90.5 (70–100) | 93 (70–100) |
SaO2 – oxygen saturation, BMI – body mass index.
Comparison between operable (GI-A) and non-operable (GI-B) PH subgroups according to different parameters
| Parameter | Total ( | Group I-A ( | Group I-B ( | Test of sig. | |
|---|---|---|---|---|---|
| Gender: | |||||
| Male | 11 (44%) | 9 (42.9%) | 2 (50%) | χ2 = 0.070 | 1.00 |
| Female | 14 (56%) | 12 (57.1%) | 2 (50%) | ||
| Age [months] | 24 (4–120) | 24 (4–60) | 57 (30–120) | 0.014 | |
| Weight [kg] | 12.2 ±5.1 | 11.1 ±3.1 | 18.4 ±9 | 0.204 | |
| Height [cm] | 81.2 ±15.4 | 77.2 ±11.4 | 102 ±18.2 | 0.001 | |
| O sat % | 90.5 ±5.7 | 91.3 ±5.5 | 86.5 ±5.4 | 0.128 | |
| Echocardiography report: | |||||
| PGTR [mm Hg] | 40.5 ±10.8 | 38.6 ±10 | 49 ±11.9 | 0.081 | |
| PGPR [mm Hg] | 29.7 ±7.5 | 28.2 ±6.6 | 36.3 ±8.5 | 0.049 | |
| IVG [mm Hg] | 26.6 ±8.8 | 26.2 ±8.4 | 28.5 ±11.8 | 0.641 | |
| Catheterization data: | |||||
| RV pressure [mm Hg] | 69.1 ±15.3 | 65.5 ±12.7 | 88 ±14.9 | 0.004 | |
| Sys/PAP [mm Hg] | 65.8 ±18.2 | 59.8 ±12.3 | 97.5 ±6.9 | < 0.001 | |
| Mean PAP [mm Hg] | 46.4 ±15.4 | 42.2 ±12.7 | 68.3 ±8.4 | 0.001 | |
| Qp : Qs | 1.74 ±0.80 | 1.92 ±0.75 | 0.81 ±0.11 | < 0.001 | |
| PVRI/SVRI | 0.25 (0.11–0.91) | 0.23 (0.11–0.30) | 0.68 (0.40–0.91) | 0.002 | |
| PVRI [WU·m2] | 0.93 (0.42–9.17) | 0.89 (0.42–1.62) | 3.62 (3.08–9.17) | 0.002 | |
| SVR [WU] | 9.9 (4.5–14.3) | 9.2 (5.2–12.8) | 11.4 (4.5–14.3) | 0.415 | |
| SVRI [WU·m2] | 4.8 ±1.9 | 4.3 ±1.4 | 7.3 ±2.4 | 0.001 | |
| PVR [WU] | 1.9 (1.2–11.8) | 1.8 (1.2–3.4) | 6 (3.9–11.8) | 0.002 | |
Qp – pulmonary vascular resistance, Qs – systemic vascular resistance, PAP – pulmonary artery pressure, PVRI – pulmonary vascular resistance index, SVRI – systemic vascular resistance index. PGTR – pressure gradient of tricuspid regurgitation, PGPR – pressure gradient of pulmonary regurgitation, IVG – interventricular pressure gradient. χ2, p – χ2 and p-values for chi-square test for comparing between the two groups. t, p – t and p-values for Student’s t-test for comparing between the two groups. U, p – U and p-values for Mann-Whitney test for comparing between the two groups.
Statistically significant at p ≤ 0.05.
Patient outcome after analysis of catheterization report
| Patient outcome | Analysis of catheterization report | |
|---|---|---|
| Group I: | ||
| Operable | 21 (84) | VSD, CAVCD, TGA, DORV |
| Sildenafil therapy 6 months | 3 (12) | 2 VSD/1 CAVCD |
| Inoperable | 1 (4) | PM wide VSD |
| Group II: | ||
| Operable | 23 (63.8) | 9 TOF, 9 VSD/PS, 3 ASD/PS, 1 DCRV |
| Palliative shunt | 9 (25) | 3 TOF/PA, 6 TOF MG < 1.2 |
| Stent dilatation | 4 (11.1) | 2 PS/LPAS, 2 TOF + bifurcation stenosis |
Distribution of matched and unmatched echo reports to catheterization reports for different cases among group II
| Diagnosis | Total ( | Unmatched ( | Matched ( | χ2 | |
|---|---|---|---|---|---|
| TOF | 17 (47.2%) | 5 (45.5%) | 12 (48.0%) | 0.020 | 0.888 |
| TOF/PA | 3 (8.3%) | 3 (27.3%) | 0 (0.0%) | 7.438 | 0.023 |
| TGA-PS | 1 (2.8%) | 0 (0.0%) | 1 (4.0%) | 0.453 | 1.000 |
| PS/LPA | 5 (13.9%) | 2 (18.2%) | 3 (12.0%) | 0.244 | 0.631 |
| DCRV | 1 (2.8%) | 0 (0.0%) | 1 (4.0%) | 0.453 | 1.000 |
| VSD + PS | 9 (25.0%) | 1 (9.1%) | 8 (32.0%) | 2.138 | 0.223 |
χ2, p – χ2 and p-values for chi-square test for comparing between the two groups.
Statistically significant at p ≤ 0.05.